Last reviewed · How we verify

Dey — Portfolio Competitive Intelligence Brief

Dey pipeline: 3 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Fluticasone Propionate (FP) Fluticasone Propionate (FP) marketed Inhaled corticosteroid Glucocorticoid receptor Respiratory / Pulmonology
Cyclamen Europaeum Cyclamen Europaeum marketed Non-Standardized Plant Allergenic Extract [EPC]
Perforomist, nebulization, COPD Perforomist, nebulization, COPD marketed Long-acting beta-2 agonist (LABA) Beta-2 adrenergic receptor Respiratory

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Organon and Co · 2 shared drug classes
  2. Teva Branded Pharmaceutical Products R&D, Inc. · 2 shared drug classes
  3. GlaxoSmithKline · 2 shared drug classes
  4. Chiesi Farmaceutici S.p.A. · 2 shared drug classes
  5. Sanofi · 2 shared drug classes
  6. SkyePharma AG · 2 shared drug classes
  7. AstraZeneca · 2 shared drug classes
  8. Fujian Medical University Union Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Dey:

Cite this brief

Drug Landscape (2026). Dey — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dey. Accessed 2026-05-13.

Related